乳腺癌患者血清瘦素及可溶性瘦素受体的作用分析

Serum Leptin and Soluble Leptin Receptor (sLR) Levels in Patients with Breast Carcinoma

目的:分析瘦素(leptin,Lp)及可溶性瘦素受体(solub le leptin receptor,sLR)水平在乳腺癌患者血清中的变化。方法:用放射免疫分析测定68例乳腺癌患者血清瘦素水平,并同步测量体重指数(MB I)和用酶联免疫吸附试验法检测可溶性瘦素受体水平,与31例良性乳腺疾病和40例健康体检者进行对照比较。结果:乳腺癌组血清瘦素水平显著高于健康对照组(P<0.01),消除体重指数的影响后,这种显著性差异依然存在;可溶性瘦素受体水平与对照组比水平下降(P<0.05),消除体重指数的影响后,这种显著性差异消失(P>0.05);良性乳腺疾病对照和健康对照之间均无显著性差异。结论:乳腺癌患者瘦素呈现过表达现象,瘦素与瘦素受体结合,促进肿瘤生长,瘦素可作为乳腺癌的潜在检测指标,其对于研究乳腺癌的发生发展、与肥胖的关系、辅助诊断乳腺癌都具有重要意义。

Objective To study the changes of serum leptin and soluble leptin receptor （sLR） levels in patietns with breast carcinoma. Methods Serum leptin （with RIA） and sLR （with ELISA） levels were determined in 68 patients with breast carcinoma 31 patients with benign breast disorders, and 40 controls. BMI was also examined in these subjects. Results Serum leptin levels in the patients were significantly higher than those in the controls （P 〈 0.01）, even after correction for the BMI differences. Serum sLR levels were significantly lower than those in the controls （P 〈 0.05）, however, after correction for BMI differences, the levels in the two groups were not much different. Levels in patients with benign breast disorders were not much different from those in controls. Conclusion Over expression of leptin was demonstrated in patients with breast carcinoma. Leptin might promote tumor growth and could be used as a tumor marker for breast carcinoma.